This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Aside from some very brief demos on code generation and literature searches, mentions of LLM applications in preclinical research were scarce. The authors provided examples where GPT-4 could provide a SMILES string, IUPAC name, or descriptive text for a marketed drug. Most of the drug discovery examples were underwhelming.
Read Programming inactive RNA-binding smallmolecules into bioactive degraders. He took products to market at prices people were willing to pay. The demos are this Sunday, June 4th! Molecular Therapy. Read Synthetic virology approaches to improve the safety and efficacy of oncolytic virus therapies. Nature Communications.
Read Programming inactive RNA-binding smallmolecules into bioactive degraders. He took products to market at prices people were willing to pay. The demos are this Sunday, June 4th! Molecular Therapy. Read Synthetic virology approaches to improve the safety and efficacy of oncolytic virus therapies. Nature Communications.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content